PA
KALV

Profund Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Profund Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$517K Buy
25,660
+1,268
+5% +$20.4K 0.02% 540
2025
Q4 		$394K Buy
24,392
+11,779
+93% +$156K 0.01% 696
2025
Q3 		$154K Buy
12,613
+2,593
+26% +$35.8K 0.01% 1014
2025
Q2 		$113K Buy
+10,020
New +$123K ﹤0.01% 956
2025
Q1 		– Sell
-10,762
Closed -$91.2K – 1050
2024
Q4 		$91.2K Buy
+10,762
New +$111K ﹤0.01% 1075

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Profund Advisors's KALV Position: Q1 2026 in Review

Profund Advisors increased its KalVista Pharmaceuticals (KALV) stake by 5.2% in Q1 2026, buying an estimated $20.4K and bringing the position to 25,660 shares worth $517K. The position accounts for 0.02% of the portfolio, ranked #540.

Profund Advisors first reported a position in KALV in Q4 2024 and has held it in 5 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Profund Advisors held 25,660 shares of KalVista Pharmaceuticals worth $517K as of Q1 2026.
  • Profund Advisors bought 1,268 KalVista Pharmaceuticals shares in Q1 2026, an estimated $20.4K.
  • KalVista Pharmaceuticals made up 0.02% of Profund Advisors's portfolio in Q1 2026, its #540 holding.
  • Profund Advisors first reported a position in KalVista Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.